The present work provides evidence that CCL5 can act through CD11bhiF4/80low TAMs indirectly, rather than directly through the CD8+ T cells, for inhibiting the accumulation of CD8+ T cells into the central area of CRC. The gene discussed is CD8A; the disease is colorectal carcinoma.